Novo Nordisk: Ozempic-Absatz, Bewertung, Dividende — lohnt sich die Aktie noch? | NVO Analyse

from Der Finanzfeuer Talk · host MB Capital Strategies

Pharma #01: Novo Nordisk (NVO) — Ozempic & Wegovy treiben das Wachstum. Dividendenrendite, Bewertung und Kurspotenzial nach dem Kursrückgang. Lohnt sich der Einstieg? Disclaimer: Keine Anlageberatung. Alle Inhalte dienen ausschliesslich der Information und Unterhaltung.

Episode metadata supplied by the publisher feed · Published May 21, 2026

Embed this episode

Attribution link and audio player

Ready to play

Novo Nordisk: Ozempic-Absatz, Bewertung, Dividende — lohnt sich die Aktie noch? | NVO Analyse

0:00 14:58

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

#26 Wie verlängert sich die Lebensdauer einer E-Auto-Batterie

Jun 19, 2024 ·20m

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Der Finanzfeuer Talk?

This episode is 14 minutes long.

When was this Der Finanzfeuer Talk episode published?

This episode was published on May 21, 2026.

Can I download this Der Finanzfeuer Talk episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!